HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 20, No 12, December 2016 – Medical Imaging Technology       » Climate Change Could Hurt Coffee, Help Banana Production       » Partnerships and Innovation: Shaping the Future of Healthcare in Asia Pacific       » Chugai's Novel Antibody Technologies Put Singapore at the Centre of Fight Against Disease       » NUS Scientists Discover the "Switch" that Makes Breast Cancer Cells Aggressive      
INSIDE INDUSTRY
Octa Phillip Bioscience Managers announces first close on new healthcare fund
Leading Australasian bioscience fund manager, Octa Phillip Bioscience Managers (Bioscience Managers), announced a successful first close on its second fund, the Asia Pacific Healthcare Fund II, which has so far attracted $55 million from Australian Institutions, IOOF and MIESF.

“The growing healthcare and life sciences sector in Australia and across the Asia Pacific region provides a unique investing opportunity, which is much more resilient than traditional commodity markets.” Bioscience Managers’ Managing Director Jeremy Curnock Cook said. “We believe that our fund offers institutional and sophisticated investors a pathway to investing in the sector that is carefully designed to minimize risk and maximize security.”

The fund has already started building its portfolio, investing $3m into ASX listed regenerative medicine company, Avita and is currently assessing a number of other companies.

Bioscience Managers has a global, multi-disciplinary team and a focus on healthcare and life sciences firms that are in or near clinical development. Their “designed for security” risk managed investment approach has resonated with their committed institutions, who recognize that the macroeconomic trends powering global demand for healthcare are set to continue, creating a period of unprecedented opportunities for skilled, specialized fund managers and their investors.

Chief Investment Officer Matt McNamara said, “We are extremely pleased to have completed a first close at $55m in a very difficult market. We would hope to raise $100m or more by our final close.”

With over 170 investments, 40+ IPO's / Reversals across Australia, the USA and Europe and investments in companies such as Chiron, Amgen and Angiotech behind him, Bioscience Managers’ Managing Director Jeremy Curnock Cook, is an expert in the field. Bioscience Managers’ first fund, the IB Australian Bioscience Fund I, is still active, has returned called capital to its investors (as of 30 June 2012) and recorded an annual IRR of 28%[2] (as at 30 Sept 2012) since its inception in 2008. Fund I's investments have included successful Australian companies such as Heartware, Acrux, Pharmaxis, Alchemia and Peplin (acquired by Leo Pharma).

Yet despite the firm's undeniable success, the current financial climate has proved a challenge. “It's inarguable that the current volatility in the financial markets is pulling funds away from growth investments, such as healthcare technology investments, and into more risk averse assets such as cash and bonds. We believe that our investment approach manages risk effectively in an industry seen by some to be a high risk environment. With a proven track record in exceeding investor expectations, we anticipate continuing to attract capital to this and other investment vehicles.” said Curnock Cook.

Fund II will remain open for investment for 12 months from its first close.

Click here for the complete issue.

NEWS CRUNCH  
news Accuron Technologies' MedTech Division Invests into AWAK Technologies
news Philips introduces PerformanceBridge suite of operational performance improvement software and services for radiology departments
news Give a Gift that Will Last a Lifetime this Holiday Season with Smile Train
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Lungs & Respiratory System
February:
Cancer Research, Treatment/Technology
March:
Traditional Chinese Medicines
April:
Eye Care/ Eye Health
May:
The Piece of Your Mind - Brain Health/Science
June:
Featuring Biotech Start-Ups/Companies
July:
Food Science & Technology
August:
Diabetics Technology
September:
No. 1 Killer - Heart Diseases, Diagnosis and Treatment
October:
Skin Diseases/Allergic Reactions
November:
Diseases threatening our Children
December:
Liver Health & Treatment/Technology
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2016 World Scientific Publishing Co Pte Ltd  •  Privacy Policy